Details of the Drug

General Information of Drug (ID: DMXSVGI)

Drug Name

Loncastuximab tesirine

Indication

Disease Entry	ICD 11	Status	REF
Diffuse large B-cell lymphoma	2A81	Approved	[1]
Follicular lymphoma	2A80	Phase 2	[2]
------------------------------------------------------------------------------------

Drug Type

Antibody drug conjugate

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 15,245-22,823 mcgday/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 2995 mcg/L [3]
Clearance: The clearance of drug is 0.499 L/day [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 7.06 - 12.5 days [4]
Metabolism: The drug is metabolized via the CYP3A4/5 [3]
Vd: The volume of distribution (Vd) of drug is 7.11 L []

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-lymphocyte surface antigen B4 (CD19)	TTW640A	CD19_HUMAN	Inhibitor	[5]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Diffuse large B-cell lymphoma

ICD Disease Classification

2A81

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
B-lymphocyte surface antigen B4 (CD19)	DTT	CD19	2.33E-24	-1.06	-1.33

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
2	ClinicalTrials.gov (NCT04699461) Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS 6). U.S. National Institutes of Health.
3	FDA grants accelerated approval to loncastuximab tesirine-lpyl for large B-cell lymphoma
4	A Phase I Study of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma. Clin Cancer Res. 2019 Dec 1;25(23):6986-6994. doi: 10.1158/1078-0432.CCR-19-0711. Epub 2019 Nov 4.
5	Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.